ValuEngine upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a sell rating to a hold rating in a report issued on Thursday morning, ValuEngine reports.
Several other research analysts also recently weighed in on the stock. LADENBURG THALM/SH SH reissued a buy rating and issued a $3.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, July 25th. Cantor Fitzgerald reissued a buy rating and issued a $22.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, May 1st. Mizuho cut their target price on shares of Marinus Pharmaceuticals from $5.00 to $1.70 and set a neutral rating for the company in a research note on Tuesday, July 23rd. Finally, Zacks Investment Research raised shares of Marinus Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, July 3rd. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $11.39.
Shares of NASDAQ:MRNS traded up $0.06 during midday trading on Thursday, hitting $1.10. 436,254 shares of the stock were exchanged, compared to its average volume of 1,780,384. Marinus Pharmaceuticals has a twelve month low of $0.77 and a twelve month high of $10.54. The firm has a 50 day simple moving average of $3.54.
Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.03). On average, equities analysts forecast that Marinus Pharmaceuticals will post -0.92 EPS for the current year.
In related news, CFO Edward F. Smith sold 24,211 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $5.03, for a total value of $121,781.33. Following the completion of the transaction, the chief financial officer now owns 20,097 shares of the company’s stock, valued at approximately $101,087.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.10% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in Marinus Pharmaceuticals by 34.7% in the 4th quarter. Geode Capital Management LLC now owns 464,483 shares of the biopharmaceutical company’s stock valued at $1,332,000 after buying an additional 119,668 shares during the period. Millennium Management LLC grew its holdings in Marinus Pharmaceuticals by 76.4% in the 4th quarter. Millennium Management LLC now owns 315,842 shares of the biopharmaceutical company’s stock valued at $906,000 after buying an additional 136,830 shares during the period. Rhumbline Advisers grew its holdings in Marinus Pharmaceuticals by 15.8% in the 1st quarter. Rhumbline Advisers now owns 55,755 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 7,592 shares during the period. Two Sigma Advisers LP purchased a new stake in Marinus Pharmaceuticals in the 4th quarter valued at about $146,000. Finally, Bailard Inc. purchased a new stake in Marinus Pharmaceuticals in the 1st quarter valued at about $138,000. Institutional investors own 63.34% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
See Also: Hedge Funds
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.